The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study).

abstract：:There is no doubt that human B cell lymphoma does not elicit a clinically sufficient T cell mediated immune response that results in tumor rejection. However, the mechanisms leading to this lack of T cell recognition and effector function are still not fully understood. Many potential mechanisms such as "ignorance" in...

journal_title：Leukemia & lymphoma

authors： Schultze JL

更新日期：1999-01-01 00:00:00

abstract：:Syndecan-1 is a transmembrane proteoglycan expressed on the surface of tumor cells of various origins including myeloma, Hodgkin's disease, and certain human immunodeficiency virus (HIV) associated lymphomas. Functional studies in myeloma reveal that syndecan-1 may act as a multifunctional regulator of cell behavior i...

journal_title：Leukemia & lymphoma

authors： Dhodapkar MV,Sanderson RD

更新日期：1999-06-01 00:00:00

abstract：:Idiotypic determinants are potential patient-specific tumor antigens in multiple myeloma (MM). In this study, we have determined the DNA sequence of the variable region of the tumor immunoglobulin (Ig) in 6 patients with MM. We then selected high affinity class I-restricted T-cell peptide epitopes in tumor Ig using tw...

journal_title：Leukemia & lymphoma

authors： Szea DM,Brown RD,Yang S,Gibson J,Ho J,Fazekas de St Groth B,Basten A,Joshua DE

更新日期：2003-09-01 00:00:00

abstract：:A 54-year-old man with chronic idiopathic myelofibrosis (CIMF) underwent RIST. His clinical course had been uneventful until day 60, when splenomegaly reappeared. Hepatic dysfunction developed on day 75. Recipient-type hematopoiesis increased to 51% on day 90. After rapid tapering of cyclosporin, serum levels of AST a...

journal_title：Leukemia & lymphoma

authors： Miyakoshi S,Kami M,Kishi Y,Murashige N,Yuji K,Kusumi E,Matsumura T,Onishi Y,Kobayashi K,Kim SW,Hamaki T,Takaue Y,Taniguchi S

更新日期：2004-12-01 00:00:00

abstract：:The number of circulating plasma cells (CPC) was determined on mononuclear cell preparations after Giemsa (morphology) and light chain staining (immunocytochemistry). Both methods gave reproducible and identical results when CPC were 1% or more. Using this limit, no CPC were observed in MGUS (0/11) and primary amyloid...

journal_title：Leukemia & lymphoma

authors： Zandecki M,Facon T,Preudhomme C,Canis F,Izydorczyk V,Lovi V,Hammad M,Bauters F,Cosson A

更新日期：1994-08-01 00:00:00

abstract：:Short responses to immunochemotherapy predict for an inferior OS in follicular lymphoma. We set out to determine whether this is also the case in marginal zone lymphoma. A group of 139 marginal zone lymphoma (MZL) patients treated with front-line immuno- or immunochemotherapy (I/ICT) were categorized into I/ICT-refrac...

journal_title：Leukemia & lymphoma

authors： Sorigue M,Bishton M,Domingo-Domenech E,McMillan A,Prusila R,García O,Kuusisto M,Condom M,Tapia G,Ribera JM,Kuittinen O,Fox CP,Sancho JM

更新日期：2019-10-01 00:00:00

abstract：:Oncoproteins play a vital role in the pathogenesis of myeloid leukemia. Most targeted therapies for myeloid leukemia are small molecules or monoclonal antibodies that inhibit the activity of the oncoproteins. However, leukemia cells often develop resistance to these drugs through overexpression of the target protein a...

journal_title：Leukemia & lymphoma

authors： Lei H,Wang W,Wu Y

更新日期：2018-10-01 00:00:00

abstract：:A recent phase III trial demonstrated improved progression-free survival (PFS) and overall survival (OS) associated with adding rituximab to fludarabine and cyclophosphamide (R-FC) compared to FC in treatment of previously untreated chronic lymphocytic leukemia (CLL). A cost-effectiveness analysis of R-FC over FC was ...

journal_title：Leukemia & lymphoma

authors： Hornberger J,Reyes C,Shewade A,Lerner S,Friedmann M,Han L,Gutierrez H,Satram-Hoang S,Keating MJ

更新日期：2012-02-01 00:00:00

abstract：:Using a non-myeloablative stem cell trasplantation (NST) program, 25 allografts were prospectively given to 24 patients with acute myelogenous leukemia (AML) eligible for conventional allografting; 2 individuals had secondary forms of AML. The median age of the patients was 35 years, with a range of 12 to 56. All pati...

journal_title：Leukemia & lymphoma

authors： Ruiz-Argüelles GJ,Gómez-Almaguer D,David-Gomez-Rangel J,Vela-Ojeda J,Cantú-Rodríguez OG,Jaime-Pérez JC,González-Llano O,Herrera-Garza JL

更新日期：2004-06-01 00:00:00

abstract：:Myelofibrosis (MF), including primary, post-essential thrombocythemia and post-polycythemia vera MF, associates with a reduced quality of life and shortened life expectancy. Dysregulation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is prominent, even in the absence of the ...

journal_title：Leukemia & lymphoma

authors： Stein BL,Cervantes F,Giles F,Harrison CN,Verstovsek S

更新日期：2015-01-01 00:00:00

abstract：:In four patients, aged 15 - 20 years, with high-risk acute myeloid leukemia (AML), high-dose samarium 153-labelled ethylenediaminetetramethylenephosphonate (153Sm-EDTMP) was used for targeted marrow irradiation before preparative chemotherapy conditioning regimens and allogeneic (three patients) or autologous (one pat...

journal_title：Leukemia & lymphoma

authors： Rodriguez V,Anderson PM,Litzow MR,Erlandson L,Trotz BA,Arndt CA,Khan SP,Wiseman GA

更新日期：2006-08-01 00:00:00

abstract：:Twenty-nine patients with non-Hodgkin's lymphoma received a single subcutaneous injection of 6 mg pegfilgrastim approximately 24 h after the start of CHOP chemotherapy. The safety of pegfilgrastim in this patient population was determined by reports of adverse events. The pharmacokinetics of pegfilgrastim were charact...

journal_title：Leukemia & lymphoma

authors： George S,Yunus F,Case D,Yang BB,Hackett J,Shogan JE,Meza LA,Neumann TA,Liang BC

更新日期：2003-10-01 00:00:00

abstract：:The increased number of CD5+ B-cells in some human autoimmune diseases, the frequent commitment of CD5+ B-cells to the production of natural autoantibodies, and the apparent involvement of these cells in the pathogenesis of the autoimmune hemolytic anemia (AIHA) in certain mouse models suggests a causal relationship b...

journal_title：Leukemia & lymphoma

authors： Efremov DG,Ivanovski M,Burrone OR

更新日期：1998-01-01 00:00:00

abstract：:Hematopoietic progenitors can be expanded ex vivo in the presence of various cytokine combinations. Since normal early progenitor or stem cells persist in the blood and bone marrow of patients with Philadelphia chromosome [Ph]-positive chronic myeloid leukaemia (CML), the selection of normal (Ph-negative) progenitor c...

journal_title：Leukemia & lymphoma

authors： Mahon FX,Pigeonnier-Lagarde V,Chahine H,Maguer-Satta V,Ripoche J,Reiffers J

更新日期：1998-12-01 00:00:00

abstract：:The cytokine IL-6 has been proposed as an autocrine growth factor in multiple myeloma, and is also required for stimulation of immunoglobulin production and secretion in normal plasma cells and myeloma cells. In this study, we showed that secreted IL-6 is detectable by Western blot analysis in a panel of lymphoid and ...

journal_title：Leukemia & lymphoma

authors： Shiao RT,McLeskey SB,Khera SY,Wolfson A,Freter CE

更新日期：1996-04-01 00:00:00

abstract：:The anemia of MDS often results in decreased quality of life, which is invoked to justify red cell transfusions; however, there are sparse data regarding the minimum hemoglobin (Hb) at which it is safe to forgo transfusions for patients with no evidence of end-organ damage. This issue is even more important in the COV...

journal_title：Leukemia & lymphoma

authors： Tanasijevic AM,Revette A,Klepin HD,Zeidan A,Townsley D,DiNardo CD,Sebert M,DeZern AE,Stone RM,Magnavita ES,Chen R,Sekeres MA,Abel GA

更新日期：2020-12-01 00:00:00

abstract：:Recent data have suggested that rituximab is an active agent for the treatment of Waldenstrom's macroglobulinemia (WM). However, the patients that are more likely to benefit have not been clearly defined. In order to address this question we evaluated 52 patients who were treated with single-agent rituximab in the con...

journal_title：Leukemia & lymphoma

authors： Dimopoulos MA,Alexanian R,Gika D,Anagnostopoulos A,Zervas C,Zomas A,Kyrtsonis MC,Anagnostopoulos N,Pangalis GA,Weber DM

更新日期：2004-10-01 00:00:00

abstract：:We report a case of double isochromosome 8q as a single cytogenetic abnormality in a patient with acute myelo-monocytic leukemia. Similarly to rare cases with tetrasomy 8, the patient showed monocytic involvement and was refractory to cytotoxic chemotherapy. We conclude that this kind of cytogenetic aberration is prob...

journal_title：Leukemia & lymphoma

authors： Vicari L,Sebastio L,Cirigliano V,Pugliese MT,Ferrara F

更新日期：1995-10-01 00:00:00

abstract：:In this study, we report that the related adhesion focal tyrosine kinase RAFTK, is an upstream kinase in beta1 integrin mediated activation of Akt. Stimulation through beta1 integrins by fibronectin reversed apoptosis induced by adriamycin. Inhibitors of phosphatidylinositol 3-kinase (PI3 kinase)/Akt (LY 294002), tyro...

journal_title：Leukemia & lymphoma

authors： Sarkar S,Svoboda M,de Beaumont R,Freedman AS

更新日期：2002-08-01 00:00:00

abstract：:It has recently been postulated that the absence of a single tumor suppressor gene (TSG) allele can provide a selective advantage for an emerging tumor cell. We have characterized the precise extension of the deletion on der(9) in 20 chronic myeloid leukemia (CML) cases using FISH analysis with an appropriate set of B...

journal_title：Leukemia & lymphoma

authors： Specchia G,Albano F,Anelli L,Storlazzi CT,Zagaria A,Liso A,Pannunzio A,Pastore D,Mestice A,Greco G,Liso V,Rocchi M

更新日期：2004-04-01 00:00:00

abstract：:We describe here a rare case of malignant lymphoma followed by plasmacytoma in Hashimoto's thyroiditis. The patient developed malignant lymphoma (small, non-cleaved cell, and non Burkitt's type by Working Formulation classification), and remained in remission for 2 years after receiving combination chemotherapy, and t...

journal_title：Leukemia & lymphoma

authors： Hasegawa Y,Itoh T,Tamagawa Y,Komeno T,Kojima H,Ninomiya H,Yatabe Y,Mori N,Nagasawa T

更新日期：1999-11-01 00:00:00

abstract：:Loss of cylindromatosis gene (CYLD) expression has been observed in various cancers, including chronic lymphocytic leukemia (CLL). As a deubiquitination enzyme, CYLD regulates the proliferation, development and activation of lymphoid cells. Here we determined the CYLD mRNA expression by quantitative polymerase chain r...

journal_title：Leukemia & lymphoma

authors： Wu W,Zhu H,Fu Y,Shen W,Xu J,Miao K,Hong M,Xu W,Liu P,Li J

更新日期：2014-03-01 00:00:00

abstract：:The standard of therapy for the high risk adult neutropenic host being treated with broad spectrum antibiotics for fever has been to continue intravenous antibiotics until neutropenia resolves. We performed a small, limited pilot study to determine if it is safe to switch these patients to oral monotherapy with ciprof...

journal_title：Leukemia & lymphoma

authors： Horowitz HW,Holmgren D,Seiter K

更新日期：1996-09-01 00:00:00

abstract：:When lymph node biopsies of lymphocytic neoplasms are studied with subtle morphological and immunohistochemical methods meaningful information is obtained, that is not only of theoretical value, but which also relates to the clinical behavior ("leukemia," paraproteinemia, prognosis). Such an analysis allows us to diff...

journal_title：Leukemia & lymphoma

authors： Lennert K,Tamm I,Wacker HH

更新日期：1991-01-01 00:00:00

abstract：:The purpose of this phase 2 study was to determine the activity and safety of six cycles of bendamustine and eight rituximab (RB) as first-line treatment of adult patients with advanced stage non-follicular indolent non-Hodgkin lymphomas (INFL). The primary end-point was the complete response rate (CRR) with expected ...

journal_title：Leukemia & lymphoma

authors： Luminari S,Goldaniga M,Cesaretti M,Orsucci L,Tucci A,Pulsoni A,Salvi F,Arcaini L,Carella AM,Tedeschi A,Pinto A,Stelitano C,Baldini L

更新日期：2016-01-01 00:00:00

abstract：:Central nervous system (CNS) relapse is a challenging complication in patients with diffuse large B-cell lymphoma (DLBCL). Thus, identification of the high-risk population, in whom prophylactic treatment may play a significant role, is critical. We calculated the incidence of CNS relapse and evaluated the risk factors...

journal_title：Leukemia & lymphoma

authors： Chihara D,Oki Y,Matsuo K,Onoda H,Taji H,Yamamoto K,Morishima Y

更新日期：2011-12-01 00:00:00

abstract：:Patients with chronic lymphocytic lymphoma (CLL) with high-risk cytogenetics [del(11q)(q22.3) or del(17p)(p13.1)] have limited therapeutic options and their prognosis remains poor. This analysis was conducted to determine the clinical activity of lenalidomide in patients with high-risk disease. Relapsed/refractory pat...

journal_title：Leukemia & lymphoma

authors： Sher T,Miller KC,Lawrence D,Whitworth A,Hernandez-Ilizaliturri F,Czuczman MS,Miller A,Lawrence W,Bilgrami SA,Sood R,Wood MT,Block AW,Lee K,Chanan-Khan AA

更新日期：2010-01-01 00:00:00

abstract：:Rituximab (IDEC C2B8) is a chimeric human-mouse monoclonal anti-CD20 antibody that has been proven to be effective for the treatment of patients with CD20 positive leukemia and lymphoma. The level of CD20-expression in patients with B-cell chronic lymphocytic leukemia (B-CLL) is low in comparison to other B-cell lymph...

journal_title：Leukemia & lymphoma

authors： Perz J,Topaly J,Fruehauf S,Hensel M,Ho AD

更新日期：2002-01-01 00:00:00

abstract：:Two patients presented with anasarca, fevers and sweats. Subsequent evaluation revealed aggressive lymphoproliferative disease. Both patients were treated with CHOP chemotherapy. One patient responded with spontaneous, vigorous diuresis and complete resolution of the edema. She relapsed two months later with recurrent...

journal_title：Leukemia & lymphoma

authors： Jillella AP,Day DS,Severson K,Kallab AM,Burgess R

更新日期：2000-07-01 00:00:00

abstract：:Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML). However, resistance is occasionally observed, mainly due to mutations within the BCR-ABL kinase domain. The T315I substitution confers complete resistance to all TKIs commonly used in clinical practice. To date, the ...

journal_title：Leukemia & lymphoma

authors： Chomel JC,Sorel N,Bonnet ML,Bertrand A,Brizard F,Roy L,Guilhot F,Turhan AG

更新日期：2010-11-01 00:00:00